{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.297","upperLimit":"0.605","value":"0.458"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"}],"units":"Participants"}],"description":"OS rate is defined as the proportion of participants alive 9 months after the start of treatment.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with Glioblastoma received epacadostat 100/300 mg BID in combination with nivolumab 240 mg IV infusion Q2W on Days 1, 15, 29, and 43 of each 8-week cycle.","id":"OG000","title":"Phase 2: Epacadostat 100/300 mg + Nivolumab 240 mg"}],"paramType":"NUMBER","populationDescription":"The Phase 2 Full Analysis Population includes all participants enrolled in the study who take at least 1 dose of study drug. The data is reported for participants with Glioblastoma cancer type for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Month 9","title":"Phase 2: Overall Survival (OS) Rate of Proportion With Glioblastoma","type":"PRIMARY","unitOfMeasure":"proportion of participants"}